PMID- 18377706
OWN - NLM
STAT- MEDLINE
DCOM- 20080722
LR  - 20190911
IS  - 1473-4877 (Electronic)
IS  - 0300-7995 (Linking)
VI  - 24
IP  - 5
DP  - 2008 May
TI  - The clinical relevance of changes in the Montgomery-Asberg Depression Rating 
      Scale using the minimum clinically important difference approach.
PG  - 1329-35
AB  - OBJECTIVE: To identify the minimal clinically important difference (MCID) for the 
      Montgomery-Asberg Depression Rating Scale (MADRS) in randomised studies of 
      depression, and to cross-validate the estimated MCID. DESIGN AND METHODS: 
      Placebo-treated patients from three similarly-designed, 8-week, double-blind, 
      randomised depression trials with a stable health status between baseline and 
      Week 1 ('no change' rating on the Clinical Global Impression-Improvement scale) 
      were eligible. To calculate the MCID using the distribution-based approach, the 
      standard deviation was estimated using baseline MADRS data while the reliability 
      parameter was measured as the intraclass correlation coefficient between baseline 
      and Week 1. For cross-validation, patients from an observational study were 
      matched to identify the 'MCID change' (MADRS change from baseline to endpoint 
      score plus the estimated MCID) and 'control' groups. Comparisons of clinical and 
      health-related quality of life measures were performed. RESULTS: In total, 177 
      placebo-treated patients were identified. MCID estimates for MADRS ranged from 
      1.6 to 1.9. A total of 105 matched pairs were identified for the cross-validation 
      analyses. Mean change from baseline in MADRS scores (10.6 +/- 8.5 vs. 12.5 +/- 
      7.9, p = 0.038) and remission rates (71.6% vs. 57.1%, p < 0.05) significantly 
      differed between the 'MCID change' and 'control' groups at endpoint. Numerically 
      higher response rates and greater improvements in HRQoL scores in the 'MCID 
      change' group were also found. CONCLUSION: These preliminary findings support the 
      value of the estimated MCID for the MADRS and may aid decision makers in 
      evaluating antidepressant treatment effects and improving long-term patient 
      outcomes.
FAU - Duru, Gerard
AU  - Duru G
AD  - CNRS (French National Center for Scientific Research), Universite Claude Bernard 
      Lyon I, France. gduru@univ-lyon1.fr
FAU - Fantino, Bruno
AU  - Fantino B
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20080328
PL  - England
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
RN  - 0DHU5B8D6V (Citalopram)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Age Factors
MH  - Aged
MH  - Citalopram/*administration & dosage/adverse effects
MH  - Cross-Sectional Studies
MH  - Depressive Disorder, Major/*diagnosis/*drug therapy
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Drug Administration Schedule
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Monitoring, Physiologic/methods
MH  - Probability
MH  - *Psychiatric Status Rating Scales
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - Risk Assessment
MH  - Severity of Illness Index
MH  - Sex Factors
MH  - Treatment Outcome
MH  - Validation Studies as Topic
EDAT- 2008/04/02 09:00
MHDA- 2008/07/23 09:00
CRDT- 2008/04/02 09:00
PHST- 2008/04/02 09:00 [pubmed]
PHST- 2008/07/23 09:00 [medline]
PHST- 2008/04/02 09:00 [entrez]
AID - 4375 [pii]
AID - 10.1185/030079908x291958 [doi]
PST - ppublish
SO  - Curr Med Res Opin. 2008 May;24(5):1329-35. doi: 10.1185/030079908x291958. Epub 
      2008 Mar 28.